Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using CRISPR technology to treat sickle cell disease.

Government approval of these groundbreaking treatments could generate an unprecedented wave of medical innovation. But gene editing therapies aren’t without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.

On this episode of Growth Stories, we dive into the science of gene editing treatments and how the boom in gene therapy drug approvals could transform the healthcare industry.

EDITOR’S NOTE: Headline graphics at 0:23 and 5:18 in this video misstate the date of publication. The year should be 2023, not 2024.

SUBSCRIBE ► https://bit.ly/3x9SKsm
Visit our website ► investors.com
Follow me on Twitter ►   / ibd_alexis  

Questions, comments, suggestions? Drop them in the comment box below. Thanks for watching!

#AlexisGarcia #IBD #InvestorsBusinessDaily